

Siklos (hydroxyurea)

Coverage Criteria:

Reserved for patients who meet all of the following criteria:

- 1. Prescribed by or in consultation with a Hematologist; and,
- 2. Age \geq 6 months \leq 12 years old; and,
- 3. Diagnosed with pediatric sickle cell anemia; and,
- 4. History of painful sickle cell anemia crisis; and,
- 5. Dose based upon the lesser of patients actual or ideal body weight rounded to the nearest 100 mg (note: dosing not to exceed 35 mg/kg/day); and,
- 6. Unable to achieve appropriate dose using other formulations of hydroxyurea (note: dose should be rounded and capsules opened and mixed into a small quantity of food).

Renewal Criteria:

1. Neutrophils are ≥2,000 to 4,000/mm³ (Note: younger patients with lower baseline counts may safely tolerate ANC down to 1,250/mm³.)

Coverage Duration:

Initial authorizations will be for 6 months. Re-authorization will be provided for 12 months.

P&T Date: 8/13/2018, 2/13/2022 Effective Date: 10/1/2018, 7/1/2023